Atlas Trials

Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.

Clinical trial NCT07207928 · COMPLETED

Trial details

NCT number
NCT07207928
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Status
COMPLETED
Study type
OBSERVATIONAL
Urothelial Cancer
Start date
2024-09-16
Primary completion
2025-02-21
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.